$360B Women's Health Ghost Market Report

This week we look at companies in women’s health and sexual health that have been acquired by CPG conglomerates.

Amboy Street Ventures (ASV) is excited to announce its latest $1m investment in Contraline, to enable the brand to conduct what is believed to be the first clinical trial on a non-hormonal male contraceptive device in over 20 years with its innovation ADAM™. The trial will launch the next generation of non-hormonal male contraceptives, increasing choice for men and achieving public health impact.

This week we look at the rise of M&A activity around women’s health and sexual health medical device innovations.

This week we discuss the rise of companies in our space joining the SPAC bandwagon.

This week we look at the growing demand for at-home birth control subscriptions.

This week we look at the incredible rise of successful companies in the menstrual market.

This week we discuss how connected breast pump and smart pelvic floor exerciser, Elvie, is one of the latest rising successes in connected health devices.

This week we consider the rise of a hybrid model of healthcare that combines bricks and mortar with Telehealth services.

This week we look at the fertility landscape following the success of Kindbody.